US · ADPT · BIOTECHNOLOGY
Adaptive Biotechnologies Corporation (ADPT) intrinsic value and stock valuation
$27.93as of 2026-11-21 · Mkt cap 3.99B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Adaptive Biotechnologies Corporation DCF and intrinsic value
InvestorsCraft values ADPT with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ADPT’s statements →
Adaptive Biotechnologies Corporation Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Scholar Rock Holding Corporation (SRRK) $48.13
- Legend Biotech Corporation (LEGN) $15.25
- IDEAYA Biosciences, Inc. (IDYA) $25.56
- Disc Medicine, Inc. (IRON) $75.14
- Beam Therapeutics Inc. (BEAM) $20.90
- Tarsus Pharmaceuticals, Inc. (TARS) $73.01
- Mineralys Therapeutics, Inc. (MLYS) $13.66
- Zai Lab Limited (ZLAB) $21.03
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $277M | $179M | $170.3M | $185.3M | $154.3M |
| Operating income | -$-57.12M | -$-162.55M | -$-227.03M | -$-200.19M | -$-208.97M |
| Net income | -$-59.5M | -$-159.49M | -$-225.25M | -$-200.19M | -$-207.28M |
| EPSd | -$-392.17K | -$-1.08M | -$-1.56M | -$-1.4M | -$-1.48M |
| Operating cash flow | -$-45.99M | -$-95.21M | -$-156.32M | -$-183.94M | -$-192.73M |
| Capital expenditure | -$-2.96M | -$-3.66M | -$-10.7M | -$-16.35M | -$-61.75M |
| Free cash flow | -$-48.95M | -$-98.88M | -$-167.02M | -$-200.29M | -$-254.47M |
| Total assets | $512.7M | $539.4M | $661.1M | $856.6M | $923.3M |
| Total debt | $280.6M | $89.4M | $98.8M | $108M | $111.7M |
| Net debt | $210.1M | $41.5M | $33.7M | $18M | -$-27.32M |
| Total equity | $225M | $202.5M | $308.3M | $464.1M | $604.1M |
| Cash and short-term investments | $227M | $222.3M | $346.4M | $498.2M | $353.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $277M | $179M | $170.3M | $185.3M | $154.3M |
| Cost of revenue | $71.4M | $72.1M | $75.6M | $57.9M | $49.3M |
| Gross profit | $205.6M | $106.9M | $94.7M | $127.4M | $105M |
| Research and development expenses | $93.8M | $103M | $122.1M | $141.8M | $142.3M |
| Selling, general and administrative expenses | $167.3M | $157.6M | $172.5M | $184.1M | $170M |
| Other expenses | $1.7M | $8.91M | $27.1M | $1.7M | $1.7M |
| Operating expenses | $262.7M | $269.4M | $321.8M | $327.6M | $314M |
| Cost and expenses | $334.1M | $341.5M | $397.3M | $385.5M | $363.3M |
| Interest income | $9.44M | $14.5M | $15.5M | $4.06M | $1.67M |
| Interest expense | $11.8M | $11.6M | $13.8M | $4.24M | $0.00 |
| Depreciation and amortization | $17.8M | $19.3M | $22.2M | $20.9M | $14M |
| Ebitda | -$-29.85M | -$-128.76M | -$-189.27M | -$-175.21M | -$-193.34M |
| Operating income | -$-57.12M | -$-162.55M | -$-227.03M | -$-200.19M | -$-208.97M |
| Total other income/expenses, net | -$-2.33M | $2.95M | $1.73M | -$-180K | $1.67M |
| Income before tax | -$-59.46M | -$-159.59M | -$-225.3M | -$-200.37M | -$-207.3M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-59.5M | -$-159.49M | -$-225.25M | -$-200.19M | -$-207.28M |
| Weighted average shares outstanding | $151.7M | $147.1M | $144.4M | $142.5M | $140.4M |
| Weighted average diluted shares outstanding | $151.7M | $147.1M | $144.4M | $142.5M | $140.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $227M | $222.3M | $346.4M | $498.2M | $353.1M |
| Net receivables | $50.4M | $41.7M | $38M | $40.1M | $17.4M |
| Inventory | $9.82M | $8.44M | $14.5M | $14.5M | $19.3M |
| Total current assets | $300.2M | $283.8M | $410.2M | $562.2M | $402.8M |
| Property, plant and equipment, net | $74.7M | $94.4M | $120.3M | $164.2M | $172.9M |
| Goodwill and intangible assets | $120.7M | $122.4M | $124.1M | $125.8M | $127.5M |
| Long-term investments | $15.9M | $33.7M | $0.00 | $0.00 | $217.2M |
| Total non-current assets | $212.6M | $255.6M | $251M | $294.5M | $520.6M |
| Total assets | $512.7M | $539.4M | $661.1M | $856.6M | $923.3M |
| Accounts payable | $6.47M | $7.26M | $7.72M | $8.08M | $3.31M |
| Short-term debt | $13.6M | $10.2M | $9.38M | $9.23M | $5.05M |
| Deferred revenue | $45.2M | $55.7M | $48.6M | $64.1M | $80.5M |
| Total current liabilities | $89.9M | $98.1M | $88M | $109.8M | $113.8M |
| Long-term debt | $267M | $79.2M | $89.4M | $98.8M | $106.7M |
| Deferred revenue, non-current | $1.01M | $27.3M | $44.8M | $58.6M | $98.8M |
| Total non-current liabilities | $197.8M | $238.8M | $264.8M | $282.7M | $205.4M |
| Capital lease obligations | $70.2M | $89.4M | $98.8M | $108M | $111.7M |
| Total liabilities | $287.7M | $336.9M | $352.9M | $392.5M | $319.2M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-1.36B | -$-1.3B | -$-1.14B | -$-919.08M | -$-718.89M |
| Accumulated other comprehensive income (loss) | $250K | $170K | $210K | -$-4.12M | -$-1.14M |
| Total equity | $225M | $202.5M | $308.3M | $464.1M | $604.1M |
| Total investments | $172.4M | $208M | $281.3M | $408.2M | $431.1M |
| Total debt | $280.6M | $89.4M | $98.8M | $108M | $111.7M |
| Net debt | $210.1M | $41.5M | $33.7M | $18M | -$-27.32M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-59.5M | -$-159.59M | -$-225.25M | -$-200.19M | -$-207.28M |
| Depreciation and amortization | $17.8M | $19.3M | $22.2M | $28.2M | $21M |
| Stock-based compensation | $51.5M | $53.6M | $0.00 | $0.00 | $0.00 |
| Change in working capital | -$-57.77M | -$-17.45M | -$-46.18M | -$-71.55M | -$-56.82M |
| Accounts receivable | -$-8.65M | -$-3.74M | $2.03M | -$-22.65M | -$-7.36M |
| Inventory | -$-1M | $1.94M | -$-2.84M | $820K | -$-5.2M |
| Accounts payable | $670K | $670K | -$-5.41M | $7.11M | $3.94M |
| Net cash provided by operating activities | -$-45.99M | -$-95.21M | -$-156.32M | -$-183.94M | -$-192.73M |
| Investments in property, plant and equipment | -$-2.96M | -$-3.66M | -$-10.7M | -$-16.35M | -$-61.75M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $38M | $77.8M | $129.7M | $2.9M | $181.2M |
| Common stock issued | $30.4M | $240K | $2.25M | $7.89M | $26.7M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $30.4M | $240K | $2.25M | $132.3M | $27.2M |
| Net change in cash | $22.4M | -$-17.18M | -$-24.97M | -$-49.03M | $15.6M |
| Cash at end of period | $73.2M | $50.8M | $65.1M | $90M | $139.1M |
| Operating cash flow | -$-45.99M | -$-95.21M | -$-156.32M | -$-183.94M | -$-192.73M |
| Capital expenditure | -$-2.96M | -$-3.66M | -$-10.7M | -$-16.35M | -$-61.75M |
| Free cash flow | -$-48.95M | -$-98.88M | -$-167.02M | -$-200.29M | -$-254.47M |
Line items
Line items
Line items
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
- CEO
- Chad Robins
- Employees
- 624
- Beta
- 2.07
Explore
Frequently asked questions
What is the intrinsic value of Adaptive Biotechnologies Corporation (ADPT)?
Adaptive Biotechnologies Corporation (ADPT) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ADPT undervalued?
ADPT trades at a price of $27.93 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.